Article Contents
- 2023 (Vol.86)
- 2022 (Vol.85)
- 2021 (Vol.84)
- 2020 (Vol.83)
- 2019 (Vol.82)
- 2018 (Vol.81)
- 2017 (Vol.80)
- 2016 (Vol.79)
- 2015 (Vol.78)
- 2014 (Vol.76)
- 2013 (Vol.74)
- 2012 (Vol.72)
- 2011 (Vol.70)
- 2010 (Vol.68)
- 2009 (Vol.66)
- 2008 (Vol.64)
- 2007 (Vol.62)
- 2006 (Vol.60)
- 2005 (Vol.58)
- 2004 (Vol.56)
- 2003 (Vol.54)
- 2002 (Vol.52)
Prostatic Cancer Presenting as an Isolated Large Lung Mass
Jong Hwan Lee (Korea Cancer Center Hospital)
Young Ahn (Korea Cancer Center Hospital)
Im Il Na (Korea Cancer Center Hospital)
Hye-Ryoun Kim (Korea Cancer Center Hospital)
Cheol Hyeon Kim (Korea Cancer Center Hospital)
Jae Cheol Lee (Korea Cancer Center Hospital)
- Downloaded
- Viewed
Abstract
A hidden primary tumor presenting as an isolated lung mass is a diagnostic challenge to physicians because the diagnosis of lung cancer is likely to be made if the histologic findings are not inconsistent with lung cancer. A large lung mass was found incidentally in a 59-year-old man. Although adenocarcinoma was diagnosed by percutaneous needle biopsy, thyroid transcription factor-1 (TTF-1) immunostaining was negative, raising suspicion that there was another primary site. There was no abnormal finding except for the lung mass on a 18FDG-PET/CT scan and the patient did not complain of any discomfort. Finally, prostatic cancer was confirmed through the study of tumor markers and prostate-specific antigen (PSA) immunostaining. Because of the rare presentation of a single lung mass in malignancies that have another primary site, physicians should carefully review all data before making a final diagnosis of lung cancer.
- keywords
- Metastasis, Prostatic Neoplasms, Thyroid Transcription Factor 1, Tumor Markers, Biological
Reference
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-45.
3. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer:an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
4. Fabozzi SJ, Schellhammer PF, el-Mahdi AM. Pulmonary metastases from prostate cancer. Cancer 1995;75:2706-9.
5. Zelefsky MJ, Eastham JA, Sartor OA, Kantoff P. Chapter 40. Cancers of the genitourinary system. In: Devita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia:Lippincott Williams & Wilkins; 2008. p. 1392-462.
6. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202.
7. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.Int J Cancer 2005;117:294-9.
8. Yamada T, Ono S, Tsuboi M, Saito H, Sato A, Matsuhashi T, et al. Low-dose CT of the thorax in cancer follow-up. Eur J Radiol 2004;51:169-74.
9. Weng MJ, Wu MT, Pan HB, Kan YY, Yang CF. The feasibility of low-dose CT for pulmonary metastasis in patients with primary gynecologic malignancy. Clin Imaging 2004;28:408-14.
10. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006;48:223-32.
11. Choi YH, Park KY, Ryoo BY, Na, II, Yang SH, Koh JS, et al. Presence of malignant mesothelial cells in the sputum. Intern Med 2008;47:57-60.
12. Moldvay J, Jackel M, Bogos K, Soltész I, Agócs L,Kovács G, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 2004;10:85-8.
13. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002;55:662-8.
- Downloaded
- Viewed
- 0KCI Citations
- 0WOS Citations